These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34971660)

  • 1. Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.
    Tang SQ; Chen L; Li WF; Chan ATC; Huang SH; Chua MLK; O'Sullivan B; Lee AWM; Lee NY; Zhang Y; Chen YP; Xu C; Sun Y; Tang LL; Ma J
    Radiother Oncol; 2022 Feb; 167():179-186. PubMed ID: 34971660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
    Lee VH; Kwong DL; Leung TW; Choi CW; O'Sullivan B; Lam KO; Lai V; Khong PL; Chan SK; Ng CY; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; So TH; Luk MY; Lee AW
    Int J Cancer; 2019 Apr; 144(7):1713-1722. PubMed ID: 30192385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.
    Kong FF; Pan GS; Du CR; Ni MS; Zhai RP; He XY; Shen CY; Lu XG; Hu CS; Ying HM
    Radiother Oncol; 2023 Aug; 185():109721. PubMed ID: 37244356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
    Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
    Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.
    Li WZ; Wu HJ; Lv SH; Hu XF; Liang H; Liu GY; Lu N; Bei WX; Lv X; Guo X; Xia WX; Xiang YQ
    JAMA Netw Open; 2021 Sep; 4(9):e2124721. PubMed ID: 34554238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
    Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma.
    Zong J; Ji P; Lin C; Zhang R; Chen Y; Lu Q; Peng X; Pan J; Lin S
    Oral Oncol; 2022 Aug; 131():105972. PubMed ID: 35728415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA.
    Yuan X; Yang H; Zeng F; Zhou S; Wu S; Yuan Y; Cui L; Feng H; Lin D; Chen Z; Liu X; Chen J; Wang F
    BMC Cancer; 2022 Aug; 22(1):858. PubMed ID: 35932022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating Postradiotherapy MRI-Detected Lymph Node Necrosis and Pre- and Posttreatment Epstein-Barr Virus-DNA for Risk Stratification in Nasopharyngeal Carcinoma.
    Cao D; Li S; Li H; Liu L; Wang X; Quan T
    J Magn Reson Imaging; 2023 Jul; 58(1):108-119. PubMed ID: 36326089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic effect of residual plasma Epstein-Barr viral DNA after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Zheng H; Zhou P; Wang J; Yu YF; Zhou R; Lin Q; Wu SG
    Cancer Med; 2023 Jul; 12(14):14979-14987. PubMed ID: 37212447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
    Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
    Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between the seventh and eighth edition of the AJCC/UICC staging system for nasopharyngeal cancer integrated with pretreatment plasma Epstein-Barr virus DNA level in a non-Chinese population: secondary analysis from a prospective randomized trial.
    Kitpanit S; Jittapiromsak N; Sriyook A; Prayongrat A; Kannarunimit D; Chakkabat C; Lertbutsayanukul C
    Jpn J Clin Oncol; 2019 Dec; 49(12):1100-1113. PubMed ID: 31334768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
    Ding C; Dai DY; Luo ZK; Wang GY; Dong Z; Qin GJ; Du XJ; Ma J
    Oral Oncol; 2024 Apr; 151():106725. PubMed ID: 38430711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.
    Dong H; Huang Z; Yang D; Li Z; Huang H; Meng Z; Qin Y; Kang M
    BMC Cancer; 2023 Jul; 23(1):673. PubMed ID: 37464319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study.
    Chen QY; Tang QN; Tang LQ; Chen WH; Guo SS; Liu LT; Li CF; Li Y; Liang YJ; Sun XS; Guo L; Mo HY; Sun R; Luo DH; Fan YY; He Y; Chen MY; Cao KJ; Qian CN; Guo X; Mai HQ
    Cancer Res Treat; 2018 Jul; 50(3):701-711. PubMed ID: 28707462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study.
    Wu YL; Yang KB; Huang Y; Shi JR; He QS; Chen L; Li WF; Huang XD; Lin L; Chen YP; Mao YP; Tang LL; Ma J
    Radiat Oncol; 2022 Aug; 17(1):138. PubMed ID: 35941674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [
    Xie HJ; Yu YF; Sun XS; Jia GD; Luo DH; Sun R; Liu LT; Guo SS; Liu SL; Chen QY; Tang LQ; Mai HQ
    Cancer Med; 2020 Dec; 9(23):8852-8863. PubMed ID: 33034945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.